Biotech Values

[zipjet]

From the GS report on MNTA, Investment Profile:

(This is a neat chart. Ranks via interpolation with MNTA then industry ranks by percent.)

Growth 73,26
Returns 98,67
Multiple 4,38
Volatility 100,25

So MNTA is growing faster, with higher ROE-like returns, a very low PE and is very volatile.

I'll buy that.

ij



The legend for the chart:

Investment Profile
The Goldman Sachs Investment Profile provides investment context for a security by comparing key attributes of that security to its peer group and
market. The four key attributes depicted are: growth, returns, multiple and volatility. Growth, returns and multiple are indexed based on composites
of several methodologies to determine the stocks percentile ranking within the region's coverage universe.
The precise calculation of each metric may vary depending on the fiscal year, industry and region but the standard approach is as follows:
Growth is a composite of next year's estimate over current year's estimate, e.g. EPS, EBITDA, Revenue. Return is a year one prospective aggregate
of various return on capital measures, e.g. CROCI, ROACE, and ROE. Multiple is a composite of one-year forward valuation ratios, e.g. P/E, dividend
yield, EV/FCF, EV/EBITDA, EV/DACF, Price/Book. Volatility is measured as trailing twelve-month volatility adjusted for dividends.